Cencora, Inc. $COR Position Boosted by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its position in Cencora, Inc. (NYSE:COR) by 13.0% in the third quarter, Holdings Channel reports. The firm owned 48,270 shares of the company’s stock after purchasing an additional 5,543 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Cencora were worth $15,086,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Cornerstone Wealth Group LLC raised its position in shares of Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after acquiring an additional 30 shares in the last quarter. Security Financial Services INC. increased its stake in Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after purchasing an additional 33 shares during the last quarter. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Hemington Wealth Management raised its holdings in shares of Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after purchasing an additional 35 shares during the period. Finally, Quadcap Wealth Management LLC lifted its position in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after buying an additional 36 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,316 shares of company stock worth $7,151,265 over the last three months. Corporate insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on COR. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $393.08.

Cencora Trading Up 2.0%

NYSE:COR opened at $359.14 on Friday. The stock has a market cap of $69.67 billion, a price-to-earnings ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54. The business has a fifty day moving average of $347.62 and a 200-day moving average of $323.87.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.